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Background: Biological disease-modifying antirheumatic drugs (bDMARDs) used in 
second-line treatment of rheumatoid arthritis (RA) are administered parenterally. However, 
so-called targeted synthetic DMARDs (tsDMARDs) – developed more recently – offer 
alternative (ie, oral) administration forms in second-line treatment. Since bDMARDs and 
tsDMARDs can be regarded as equal in terms of efficacy, the present study examines whether 
such characteristics as route of administration drive RA patients’ treatment choice. This may 
ultimately suggest superiority of some second-line DMARDs over equally effective options, 
at least according to RA-patient preferences.
Objective: The current study assessed the importance of oral administration among other 
treatment characteristics differing between available second-line DMARDs for RA patients’ 
preferences using a discrete-choice experiment (DCE).
Materials and methods: The DCE involved scenarios of three hypothetical treatment options 
in a d-efficient design with varying levels of key attributes (route and frequency of administra-
tion, time till onset of drug effect, combination therapy, possible side effects), as defined by 
focus groups. Further patient characteristics were recorded by an accompanying questionnaire. 
In the DCE, patients were asked to choose best and worst options (best–worst scaling). Results 
were analyzed by count analysis and adjusted regression analysis.
Results: A total of 1,588 subjects completed the DCE and were eligible for final analyses. 
Across all characteristics included in the DCE, “oral administration” was most desired and 
“intravenous infusion” was most strongly rejected. This was followed by “no combination with 
methotrexate” being strongly preferred and “intake every 1–2 weeks” being strongly rejected. 
On average, levels of route of administration showed strongest influences on patients’ decisions 
in post hoc bootstrapping analysis.
Conclusion: According to the results, an oral DMARD that does not have to be combined 
with methotrexate and is not administered (only) every 1–2 weeks appears a highly favorable 
treatment option for patients with RA. DMARDs meeting these preferences may increase 
compliance and adherence in RA treatment.
Keywords: rheumatoid arthritis, disease-modifying antirheumatic drugs, patient preferences, 
discrete-choice experiment, best–worst scaling
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated 
with multisystemic manifestations, characterized by persistent inflammatory synovitis 
of peripheral joints in symmetric distribution, which causes cartilage damage and 
bone erosion.1 In addition, RA patients display a variety of other clinical features, 
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such as pain, morning stiffness, weakness, fatigue, fever, 
weight loss, and depression.2 The prevalence of RA varies by 
population, with Europe yielding prevalence rates between 
0.32% in France and 0.89% in the UK3 and somewhat larger 
prevalence rates around 1% reported for the US.4 Typically, 
females are affected approximately two to three times more 
often than males.4,5 RA can occur at any age, but typically 
manifests between 40 and 70 years of age,2 with a peak of 
disease manifestation at 56 years of age in Germany.6
Pharmacological treatment of RA rests mainly on disease-
modifying antirheumatic drugs (DMARDs). These agents 
target altered inflammatory processes in RA, aiming to 
reduce symptoms of increased inflammation and associated 
negative outcomes, such as progression of joint damage, dis-
ability, impairment, and negative impact on quality of life.7 
Like any disease-modifying medication, DMARDs have to 
be taken continuously to alter disease progression. Various 
DMARDs are available, differing with respect to the exact 
physiological processes they target. Such physiological dif-
ferences constitute differences also in terms of more practical 
characteristics of the drugs, such as mode of administration 
(eg, oral, subcutaneous, and intravenous [IV]), frequency 
of administration (daily, weekly, monthly), or necessity to 
monitor blood values.
According to current treatment recommendations by both 
the European League Against Rheumatism (EULAR)7 and 
the American College of Rheumatology (ACR),8 two major 
classes of agents are suggested for second-line treatment 
of RA, ie, treatments that should be used if conventional 
DMARDs have failed: biologic (b)-DMARDs and targeted 
synthetic (ts)-DMARDs, with the latter developed more 
recently.7 Both bDMARDs and tsDMARDs show similar 
efficacy in clinical settings,8–10 but differ with respect to other 
potentially relevant characteristics: whereas bDMARDs 
are all administered parenterally, tsDMARDs are admin-
istered orally. This also comes with a more frequent intake 
of tsDMARDs relative to bDMARDs. In addition, some 
bDMARDs are recommended only in combination with 
methotrexate (MTX), while currently approved tsDMARDs 
can also be taken as monotherapy.
Importantly, practical characteristics of treatments, such 
as route or frequency of administration, may determine the 
convenience of drug intake and thereby impact on patients’ 
compliance with prescribed treatments outside clinical set-
tings. In other chronic diseases, there is evidence to suggest 
that parenteral modes of administration are associated with 
certain barriers perceived by patients, which in turn may lead 
to reduced adherence to prescribed treatments.11–13 Therefore, 
real-life efficacy of treatments will depend not only on their 
clinical efficacy but also on treatment characteristics impact-
ing on patient adherence.
Since it has been recognized that patient preferences play 
an important role in adherence to prescribed medication,14–17 
the patient perspective is increasingly important in assessing 
a therapy’s value. Treatment regimens in line with patient 
preferences will be more likely associated with higher drug 
satisfaction and willingness to adhere to one’s prescription, 
which will ultimately lead to higher real-life efficacy. In line 
with this reasoning, EULAR and ACR recommendations7,8 
suggest a process of shared decision making between rheuma-
tologists and patients, taking into account patient preferences 
when choosing a suitable medication.
To inform decision making, particularly with regard to 
the importance of oral administration for RA-patient prefer-
ences, a quantitative approach is needed, evaluating such 
characteristics within the framework of other key treatment 
characteristics that differ meaningfully between available sec-
ond-line DMARD options. Initially, the present investigation 
used focus groups to establish which characteristics differing 
between tsDMARDs and bDMARDs generally mattered to 
RA patients (ie, aspects of route of administration, frequency 
of administration, time till onset of drug effect, combination 
therapy with MTX, and possible side effects). However, this 
technique was considered only for preliminary investigation, 
as it lacks the capability to quantify exactly the relative impor-
tance of treatment characteristics (eg, how much more or less 
important is oral relative to other forms of administration?).
Although there is a profound body of evidence regard-
ing medication preferences in the RA-patient population,18 
most studies have only elicited direct preference statements 
from patients, eg, by rating scales or rankings.19–24 With 
such methods, values assigned by respondents often violate 
certain statistical assumptions, which is likely due to con-
founding factors, such as limited attention or memory span.25 
Therefore, just like focus groups, direct preference mea-
surements represent a valid strategy to determine treatment 
characteristics that generally matter to patients, but are less 
suited to quantify the exact degree to which they matter.
More precise preference measures can be obtained by 
choice-based, indirect measurement techniques, ie, so-
called discrete-choice experiments (DCEs), increasingly 
used in health care research.25 Instead of directly asking 
individuals to state their preferences, DCEs infer prefer-
ences based on choices. Individuals are asked to choose their 
preferred option among different (hypothetical) alternatives. 
Alternatives are composed of multiple “attributes” (eg, mode 
of administration) with varying “levels” (eg, oral, subcutane-
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Patient preferences in rheumatoid arthritis
composed sets of alternatives, ie, alternatives in which levels 
of all attributes have been independently combined with one 
another. Due to repeated decisions in an orthogonal design, 
this procedure renders a less complex task (only a subset of 
levels is presented at a time for each decision) that is less 
prone to measurement errors and violation of statistical 
assumptions than direct preference statements. The exact 
influence of the varying levels on choices can be quantified 
through statistical modeling.
A special case of the DCE is so-called best–worst scaling 
(BWS).25,26 Other than traditional DCEs, BWS requires 
respondents not only to decide on the most preferred option 
but also to decide on the least preferred (worst) option, which 
renders richer information in less time. Moreover, subjects 
seem to make more consistent choices if they have to con-
sider the extremes (“best” and “worst”), rather than having 
to choose only the best option.27
The current study attempted a precise quantification 
of RA-patient preferences by implementing a DCE with 
BWS. Attribute levels used in the DCE had been previously 





This research was conducted as a questionnaire-based non-
interventional study with patients treated by rheumatologists 
all over Germany. Questionnaires were sent to participating 
rheumatologists, who distributed them to patients meeting 
inclusion criteria and agreeing to participate. Patients returned 
their questionnaire by mail or completed an online version 
of the questionnaire. No personal information that would 
allow associating responses with an individual patient was 
recorded. Due to the lack of personal information, neither 
formal informed consent nor an ethic approval were neces-
sary in accordance with the WMA Declaration on Ethical 
Considerations Regarding Health Databases and Biobanks, 
because this survey was not considered as intervention.
study population
Based on the prevalence of approximately 440,000 RA 
patients in Germany, ie, 0.65% of the German population,28 we 
aimed to include at least 1,574 RA patients for final analyses 
to estimate patient preferences with high precision. Using this 
sample size, the quantity of any trait could be estimated with 
a sampling error of 5% and a confidence interval (CI) of 95%. 
The following inclusion criteria were to be met by patients: 
subjects had to be diagnosed with RA, at least 18 years of age, 
show a sufficient level of proficiency in the German language, 
and be treated with at least one DMARD.
choice of attributes and levels
Discussions with focus groups were conducted to identify 
relevant DMARD attributes and their levels to be used in 
the final DCE. Separate focus groups took place in Munich 
and Berlin, Germany, including patients diagnosed with RA 
(Munich, n=12; Berlin, n=8).
An initial list of attributes and their levels based on 
available second-line DMARDs currently recommended 
by the EULAR7 and ACR8 was presented to participants at 
the outset of discussion. Effectiveness was excluded from 
discussion, as relevant second-line DMARDs do not differ in 
this respect.9,10 Patients were asked to add further important 
attributes they felt were missing to the list.
After discussion on why these attributes felt important and 
in how far their different levels presented a perceivable and 
meaningful difference, each patient was asked to rank attri-
butes in order of their subjective importance. Based on these 
ranking results, the following attributes (and pertaining levels; 
see Table 1) were included in the DCE: “mode of administra-
tion”, “frequency of administration”, “time till onset of drug 
effect”, “necessity of combination therapy”, and “possible 
side effects”. Table 1 lists relevant levels per attribute that 
were agreed to present a perceivable and meaningful differ-
ence, and thus were used for construction of the DCE.
Questionnaire
The main part of the questionnaire consisted of the DCE with 
eight scenarios (ie, decision cards), each presenting three 
hypothetical treatment alternatives with varying levels of the 
same attributes (multiprofile case or “case 3” design). Patients 










Once every 1–2 weeks
Once every 4–8 weeks
Once every 6–12 months
Time till onset of  
drug effect
Up to 1 month
More than 1 month up to 3 months
combination therapy Treatment requires administration of MTX 
once a week
no combination necessary
Possible side effects infections
Allergic reactions
Deterioration of laboratory values
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were asked to choose the best and worst treatment options 
on each decision card, ie, each respondent had to make eight 
“best” and eight “worst” choices. Table 2 gives an example 
of a decision card used in the questionnaire.
For the DCE, attribute levels were combined in a d-efficient 
design using the Fedorov algorithm.29 The d-efficient 
approach retains optimal orthogonality in a fractional design 
while excluding unrealistic level combinations (ie, “infusion, 
two times daily” and “oral intake, once every 6–12 months”) 
and reducing the number of necessary combinations rela-
tive to a full orthogonal design. The initially required 16 
decision cards (scenarios) for an optimal design were con-
sidered too taxing for patients, so cards were equally divided 
across two otherwise-identical versions of the questionnaire 
(blocked design), resulting in eight BWS scenarios per 
questionnaire (subject). Blocked designs have been shown 
to increase response efficiency and thus the validity of DCE 
results.30 The remainder of the questionnaire consisted of 
items on sociodemographic and disease-/treatment-related 
patient characteristics, as well as an assessment on beliefs 
about medicine.
To secure anonymity of data, age of participants, dura-
tion of symptoms, and onset of RA (disease duration) 
were recorded in categories. Categorization of duration of 
symptoms and onset of RA (disease duration) allowed for 
differentiation between early RA (,2 years) and estab-
lished RA ($10 years). Disease activity was assessed 
using the Rheumatoid Arthritis Disease Activity Index 
(RADAI)-5,31,32 offering a validated quick self-assessment 
of RA activity.
To derive experience with injectables, patients were 
asked to provide information on their DMARD medication. 
In addition, patients were asked to report whether they were 
currently receiving injectables for other diseases. Satisfaction 
with efficacy and tolerability of current DMARD medica-
tion were each rated by patients on a 5-point Likert scale. 
Beliefs about current DMARD treatment were assessed 




For all sociodemographic and disease-/treatment-related 
variables, absolute and relative frequencies were calculated 
(n, %). The RADAI-5 score was calculated as the mean 
across the five items of the instrument (each evaluated on 
a 10-point Likert scale ranging from 1= “not at all active” 
to 10= “extremely active”), with mean scores #1.4 indi-
cating remission-like, 1.6–3 mild, 3.2–5.4 moderate, and 
5.6–10 high disease activity.32,36
For the modified BMQ, item values (1= “disagree”, 
2= “uncertain”, or 3= “agree”) were added separately for items 
capturing “necessity” toward current DMARD treatment 
(three items) and “concern” (six items), with sums #6 (.6) 
indicating low (high) necessity and sums ,12 ($12) indicat-
ing low (high) concern. Moreover, based on their responses in 
the BMQ, patients were classified according to the necessity–
concern framework, as presented in Table 3.37
For analysis, patient responses on the 5-point Likert 
scales regarding drug satisfaction (efficacy and tolerability 
of current DMARD medication) were recategorized into “not 
satisfied” (including values of 1= “not at all satisfied” and 
2= “not satisfied”), “neither” (value of 3), and “satisfied” 
(including values of 4= “satisfied” and 5= “very satisfied”).
Preference data (Dce)
Data from the DCE was analyzed by both count analysis38 
and regression analysis.25 While count analysis offers an eas-
ily accessible and interpretable method to infer the relative 
importance of attribute levels for patient choices, (adjusted) 
regression analysis allows the assessment of statistical sig-
nificance of their importance while controlling for potential 
confounders (ie, sociodemographic and disease-/treatment-
related variables).
Table 2 example of a decision card (Dce scenario) used in the questionnaire
Attribute Treatment 1 Treatment 2 Treatment 3
route of administration subcutaneous self-injection intravenous infusion Pill
Frequency of administration Once every 6–12 months Once every 1–2 weeks Twice daily
Time till onset of drug effect Up to 1 month More than 1 month up to 3 months Up to 1 month
MTX combination therapy MTX once a week no MTX combination necessary MTX once a week
Possible side effects infections Allergic reactions Deterioration of laboratory values
Treatment i like best   
Treatment I find worst   
Abbreviations: Dce, discrete-choice experiment; MTX, methotrexate.
Table 3 Classification according to necessity–concern framework
Low necessity High necessity
Low concern indifferent Accepting
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Patient preferences in rheumatoid arthritis
Count analysis is solely based on frequencies of BW 
choices. The importance of an attribute level is calculated 
as the difference between percentages of the level being 
included in treatment options chosen as “best” minus per-
centages of the level being included in options chosen as 
“worst” across all choices. Positive BW scores indicate an 
attribute level to be predominantly associated with “best” 
choices; conversely, negative BW scores indicate it to be 
predominantly associated with “worst” choices. In contrast, 
BW scores near 0 indicate levels that are either chosen less 
often or chosen as best and worst similarly often, indicating 
levels that do not contribute to choices (ie, are meaningless in 
terms of patient preferences). Higher absolute values of BW 
scores thus reflect a stronger influence of an attribute level 
on choices; ordering BW scores according to their absolute 
values gives a ranking of levels in terms of their importance 
for patient preferences.27,38,39
For regression analysis, the paired-model approach of 
Flynn et al25 was used. The dependent variable in this model 
is the natural log of the total number of times a particular BW 
pair is chosen across scenarios (ie, a particular level chosen 
best with another particular level chosen worst), adjusted for 
the total number of times the pair was presented (number 
of scenarios × number of participants). Adjusted counts 
are modeled with a linear weighted-least-squares model. 
Attribute levels are entered as effect-coded explanatory 
variables (value =1 if coded level is chosen best, value =-1 
if coded level is chosen worst, value =0 if coded level is not 
chosen). Derived β-weights reflect the rate of change from 
the expected choice frequency (ie, if all choices were made 
randomly) implied by a level, which is interpreted as the 
utility of that level.25,40 Positive β-values indicate deviations 
toward “best” decisions, and negative β-values indicate 
deviations toward “worst” decisions.
The final model involved an adjusted regression analysis 
including all sociodemographic and disease-/treatment-related 
variables (patient variables age, sex, onset of RA, duration 
of symptoms, route of current DMARD administration, any 
current injectable, RADAI-5, BMQ classification, satisfac-
tion with efficacy/tolerability) as effect-coded covariates 
(value =1 if coded category is present, value =0 if coded 
category is not present). Since in the final model, β-weights 
of effect-coded covariates correspond to deviations from 
the grand mean, higher absolute values indicate that in a 
given group of patients (eg, females) choices of some BW 
pairs occur either less often (negative β-weight) or more 
often (positive β-weight) than would be expected from the 
grand mean across all patients (ie, if all patients made the 
same choices).
The final equation of the model is as follows. Note that in 
effect coding one level (category) per attribute (variable) is 
omitted and used as reference (we used levels with the lowest 
BW scores per attribute from count analysis as references; 
for ordinal covariates, the lowest category per variable was 
chosen; for nominal variables an arbitrary reference category 
was used):
ln(f) = constant + β11 pill + β12 subcutaneous + β21 
twice daily + β22 every 4–8 weeks + β23 every 6–12 
months + β31 no combination + β41 allergic reac-
tions + β42 infections + β51 age 25–49 years + β52 
age 50–64 years + β53 age $65 years + β61 female + 
β71 onset 2–,5 years + β72 onset 5–,10 years + β73 
onset $10 years + β81 duration 2–,5 years + β82 dura-
tion 5–,10 years + β83 duration $10 years + β91 current 
DMARD oral + β101 any current injectable yes + β111 
RADAI low + β112 RADAI moderate + β113 RADAI 
high + β121 BMQ accepting + β122 BMQ skeptical + β123 
BMQ indifferent + β131 satisfaction efficacy neither + β132 
satisfaction efficacy satisfied + β141 satsifaction tolerability 
neither + β142 satisfaction tolerability satisfied.
In the DCE design (multiprofile case or “case 3” design), 
patients had to choose whole options consisting of varying 
level combinations while key attributes were kept constant. 
The relative importance of the attributes for patient choices 
would thus be a mere function of their levels’ importance; 
there was no independent contribution of attributes per se to 
the participants’ choices that could be defined in the regres-
sion model (for a different design, see Flynn et al25).
Post hoc bootstrapping analysis
An estimate of the attributes’ relative importance was derived 
by calculating the mean maximum span between the levels’ 
regression coefficients per attribute (ie, difference between 
β-values of the most favored and the least favored level of an 
attribute) from 1,000 bootstrap samples. Adjusted regression 
and the maximum span between levels’ β-values per attribute 
(relative importance) were recalculated for each bootstrap 
sample to determine the attributes’ mean relative impor-
tance (mean maximum span) and their 95% CIs (percentiles 
2.5 and 97.5 of the resulting distribution).
Results
sample data
Patients were recruited from 44 rheumatologic practices 
across Germany, corresponding to 4% of German practitioners 
subspecialized in rheumatology.41 All participating physicians 
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were female (74%), 50–64 years of age (45%), reported less than 
10 years of disease duration (55%), mild-to-moderate disease 
activity (63%), and were receiving some injectable DMARD 
(54%); considering other medication also, overall 57% were 
currently receiving some injectable (for details, see Table 4).
According to the modified BMQ, most patients were 
classified as “accepting” toward their medication (patients 
associating their medication with high necessity and low 
concern). This was also reflected by the majority of the 
patients being satisfied with the efficacy and tolerability of 
their current treatment (see Table 5). However, a considerable 
percentage of the sample (20.1%) was classified as having an 




Results from count analysis can be seen in Table 6. Based 
on absolute values of the BW scores, it can be suggested 
that choices were influenced most strongly by pill (0.285), 
IV infusion (-0.24), combination with MTX (-0.176), 
and intake every 1–2 weeks (-0.175). Therefore, options 
characterized by oral intake were most strongly preferred, 
whereas options entailing IV infusion, combination therapy 
with MTX, and intake once every week or second week were 
most strongly rejected.
Adjusted regression analysis
Figure 1 shows results of adjusted regression analysis for 
β-values of the attribute levels. The β-values of confounders 
(plus constant) are given separately in Table 7, as their values 
cannot be directly compared with those of the attribute levels 
(ie, different effect codes were used with values of 1 and –1 
for best and worst choices, respectively, vs a value of 1 if 



















Onset of RA (time of diagnosis)
#2 years ago 176 (11.1)
$2,5 years ago 302 (19)
$5,10 years ago 399 (25.1)
$10 years ago 700 (44.1)
Duration of symptoms
#2 years 118 (7.4)
$2,5 years 281 (17.7)
$5,10 years 389 (24.5)






Current mode of DMARD administrationa
injectable 863 (54.4)





Notes: aBased on current DMArD treatment with its exact mode of administration; 
bbased on current DMArD treatment with its exact mode of administration and 
other current medication being received due to any comorbid diseases. Missing 
values per variable not shown.
Abbreviations: rA, rheumatoid arthritis; rADAi, rheumatoid Arthritis Disease 
Activity index; DMArD, disease-modifying antirheumatic drug.


























Notes: aBased on low/high necessity and concern combinations; high-necessity–high-
concern combinations indicate ambivalent, high-necessity–low-concern combinations 
indicate accepting, low-necessity–high-concern combinations indicate skeptical, and 
low-necessity–low-concern combinations indicate indifferent patients.37 Missing 
values per variable not shown.
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Patient preferences in rheumatoid arthritis
Table 6 results of count analysis
Attribute (levels) Chosen best Chosen worst BW score
Frequency % Frequency %
Mode of administration
iV infusion 2,781 21.9 5,832 45.9 -0.24
Pill 6,234 49.1 2,617 20.6 0.285
sc self-injection 3,689 29 4,255 33.5 -0.045
Administration frequency
Twice daily 2,633 36.6 2,208 30.7 0.059
every 1–2 weeks 2,794 23.5 4,877 41 -0.175
every 4–8 weeks 4,489 40.4 3,340 30 0.103
every 6–12 months 2,788 35.2 2,279 28.8 0.064
Combination therapy
combination with MTX 4,168 22.8 7,382 40.5 -0.176
no combination with MTX 8,536 43 5,322 26.8 0.162
Possible side effects
laboratory values 3,303 26 5,038 39.7 -0.137
Allergic reactions 5,180 40.8 3,461 27.2 0.135
infections 4,221 33.2 4,205 33.1 0.001
Time till onset of drug effect
Up to 1 month 7,542 36.6 6,426 31.2 0.054
Up to 3 months 5,162 29.5 6,278 35.9 -0.064
Notes: BW scores correspond to difference of percentage. An attribute level was included in treatment options chosen as best minus percentage; it was included in options 
chosen as worst across all times of presentation (eg, iV infusion: 21.9%–45.9% =0.219–0.459=-0.24). A positive BW score indicates an attribute level to be predominantly favored 
by patients; conversely, a negative BW score indicates a dislike of the level, and a BW score near 0 indicates that the level did not play a marked role in patients’ choice.
Abbreviations: BW, best–worst; iV, intravenous; sc, subcutaneous; MTX, methotrexate.
Figure 1 results of adjusted regression analysis (attribute levels).
Notes: ***P,0001. no P-values or cis (lower/upper bound) computed for reference levels from effect coding. reference levels in effect coding are indicated by (-). 
Attribute levels’ positive β-weights reflect biases toward “best” choices and negative β-weights reflect biases toward “worst” choices.
Abbreviations: n.s., not significant; CI, confidence interval.
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category of a covariate was present; for different interpreta-
tions of β-values, see notes below Figure 1 and Table 7).
Mean relative importance
Table 8 gives the results of the post hoc bootstrapping analy-
sis. On average, levels of route of administration were asso-
ciated with largest differences between lowest and highest 
β-weights (highest mean relative importance). This was 
followed by (in descending order): combination therapy with 
MTX, frequency of administration, possible side effects, and 
time till onset of drug effect. Notably, none of the attributes’ 
CIs overlapped with zero.
summary of results
On average, levels of route of administration influenced 
choices most strongly. This was followed by combination 
therapy, frequency of administration, possible side effects, 
and time till onset of drug effect (in this order). None of the 
attributes’ CIs overlapped with 0. As such, on average, all 
attributes were important for patients’ choices, though to a 
significantly different degree.
Patient choices, as yielded from count as well as regres-
sion analysis, were most influenced by clear preference of oral 
administration (pill) and rejection of IV infusion. These most 
important levels were followed (in descending order) by: rejec-
tion of “administration every 1–2 weeks”, rejection of “com-
bination with MTX”, and acceptance of “allergic reactions” as 
possible side effects. Less pronounced influences were found 
for “subcutaneous self-injection” (rejected) and administration 
“every 6–12 months” or “every 4–8 weeks” (both preferred). 
Administration frequency of “twice daily” and “infections” 
as side effects did not matter for patients’ choice.
Discussion
The present study aimed to determine the relative importance 
of DMARD characteristics for RA-patient preferences. 
This was achieved by using the well-established technique of 
a DCE. We used two different approaches to analyze choices 
Table 7 results of adjusted regression analysis (patient variables)
Attributes 
(levels)









25–49 years 0.017 0.005 0.005 0.030
50–64 years 0.165 ,0.0001 0.153 0.176
65+ years 0.155 ,0.0001 0.142 0.167
sex
Male -0.125
Female 0.125 ,0.0001 0.119 0.131
Onset of rA
,2 years ago -0.263
2,5 years ago -0.123 ,0.0001 -0.135 -0.111
5,10 years ago -0.012 0.054 -0.024 0.0002
$10 years ago 0.397 ,0.0001 0.382 0.413
Duration of symptoms
,2 years 0.029
2,5 years 0.082 ,0.0001 0.069 0.096
5,10 years 0.012 0.066 -0.001 0.024
$10 years -0.123 ,0.0001 -0.139 -0.108
DMArD administration
injectable 0.298
Oral only -0.298 ,0.0001 -0.312 -0.284
Any current injectable
Yes 0.242
no -0.242 ,0.0001 -0.256 -0.229
rADAi-5
remission-like 0.029
low 0.11 ,0.0001 0.101 0.119
Moderate -0.007 0.111 -0.015 0.002
high -0.132 ,0.0001 -0.142 -0.122
categorization (BMQ)
Ambivalent -0.005
Accepting 0.258 ,0.0001 0.248 0.268
skeptical -0.086 ,0.0001 -0.105 -0.066
indifferent -0.168 ,0.0001 -0.185 -0.15
Satisfaction with efficacy
Unsatisfied -0.078
neither -0.089 ,0.0001 -0.100 -0.079
Satisfied 0.167 ,0.0001 0.158 0.176
satisfaction with tolerability
Unsatisfied -0.11
neither -0.113 ,0.0001 -0.124 -0.102
Satisfied 0.223 ,0.0001 0.215 0.232
Notes: no P-values or cis (lower/upper bound) computed for reference categories 
from effect coding. reference categories in effect coding for patient variables were the 
following: ,25 years (age), male, ,2 years (onset of rA and duration of symptoms), 
injectable (current mode of DMArD administration), yes (any current injectable), 
remission-like, ambivalent (BMQ categorization), and unsatisfied (satisfaction with 
efficacy and tolerability). Positive β-values indicate best–worst pairs chosen more 
often and negative β-values best–worst pairs chosen less often than would be 
expected if all best–worst pairs were chosen equally often by all patients.
Abbreviations: rA, rheumatoid arthritis; DMArD, disease-modifying antirheumatic 
drug; rADAi, rheumatoid Arthritis Disease Activity index; BMQ, Beliefs about 
Medicines Questionnaire; CI, confidence interval.
Table 8 Mean relative importance of attributes and 95% ci







route of administration 
with MTX
0.653 0.611 0.693
combination therapy 0.471 0.438 0.504
Frequency of administration 0.396 0.357 0.436
Possible side effects 0.361 0.326 0.398
Time till onset of drug effect 0.186 0.150 0.221
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made by RA patients in the DCE: simple count analysis and 
more refined adjusted regression analysis. The order of the 
attribute levels’ importance as defined by count analysis was 
almost entirely reflected by sizes of the levels’ regression 
weights (β-values) in regression analysis. Slight differences 
were certainly due to a more precise modeling approach with 
adjusted regression analysis.
The impact of “pill” on choices outperformed that of 
all other attribute levels. It may thus be concluded that this 
feature drove patients’ choices most decisively, representing 
the most important and desired treatment characteristic in our 
study. Further important levels for treatment decision were 
(in descending order): administration “every 1–2 weeks” and 
“combination with MTX” being rejected (“no combination 
with MTX” being preferred), and “allergic reactions” being 
most accepted possible side effects. Our results suggests 
a nonlinear, U-shaped relation between patients’ choices 
and frequency of administration with indecisive attitude to 
high frequency of intake (twice daily), rejection of medium 
frequencies (every 1–2 weeks), and preference for low fre-
quencies (every 6–12 months or every 4–8 weeks).
Besides twice-daily administration, as chosen in our 
study, once-daily administration may be considered a rel-
evant frequency, especially for oral drug administration. We 
chose twice daily for several reasons. Levels were pretested 
in focus groups; if focus group members had mentioned a 
potential influence on patient preferences by differentiating 
between once and twice daily, this would have been included 
as a separate level in our study design. Further, the aim of 
our study was a setting of features typical of second-line 
treatment of RA with DMARDs. At the time of the study’s 
design, there was no once-daily treatment available. More-
over, we assumed twice-daily administration as perceived to 
be “worse” to once-daily administration, allowing the conclu-
sion that once-daily administration would be even better.
Regression analysis revealed that preferences per-
sisted even when controlled for potential influences from 
patient characteristics (covariates, eg, age, sex). Therefore, 
the attribute levels’ influences on choices reflect a more 
general nature of RA-patient preferences independently of 
individual patient characteristics. The strength of our study 
lies in the fact that included attribute levels were derived 
from available second-line DMARDs, thus presenting real-
istic treatment characteristics and increasing the ecological 
validity of our study. In addition, attribute levels had been 
previously checked for their general importance in focus 
groups, assuring that only treatment characteristics that really 
mattered to patients were included. Moreover, the DCE 
consisted of a so-called case 3 design involving scenarios 
with different multiattribute-treatment options presented to 
patients in parallel. This guaranteed a more realistic task, ie, 
it increased the ecological validity of our study, as patients 
would be presented with multiattribute treatments in the 
real world too.
The age and sex distribution of our sample was almost 
identical to data from the German Rheumatism Research 
Center, representing the most comprehensive register on the 
RA-patient population in Germany.6 Sample characteristics 
thus suggest a rather representative sample of the German 
RA population.
However, there are also certain limitations to our study. 
We included only outpatients, and thus cannot know how far 
results can be generalized to hospitalized patients as well. 
Moreover, although patient characteristics suggest a repre-
sentative sample, we had no control over patient selection 
or dropouts, and thus our study probably did not include a 
random sample but was biased toward more motivated and 
compliant patients. In general, self-reports by patients may 
render high validity of preference data, but we had no means 
to check up on the validity of medically relevant information, 
such as current medication. Similarly, disease activity was 
assessed only by a validated self-assessment tool (RADAI-5), 
which shows sufficient correlation with clinical parameters, 
but cannot be taken as their equivalent.
With regard to our findings in light of previous research, 
at the time our study was conducted, to our knowledge there 
were only three studies assessing patient preferences toward 
DMARDs using a DCE approach that had been published in 
peer-reviewed journals,42–44 although none used BWS. While 
Skjoldborg et al42 did not include any levels of “route of 
administration” in their experiment and focused on a different 
research question, Poulos et al44 included only “injection at 
home” and “infusion at doctor’s site”, and thus neither con-
sidered all relevant characteristics of route of administration 
for currently available options in second-line treatment.
Augustovski et al43 were the only ones to include oral 
administration in their DCE. Similarly to our results, they 
demonstrated a preference for pills over parenteral (IV) 
routes of administration in RA patients. Our findings are thus 
generally in line with their study,43 and add to similar find-
ings with other diseases using different methodologies.11–13 
However, the ability of Augustovski et al43 to quantify exactly 
the relative importance of oral administration was limited, 
due to the coding procedure they used.
Our finding of a strong rejection of IV infusion is in 
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other approaches than DCE.18 On the contrary, it has been 
reported that combination therapy with MTX is usually well 
accepted by RA patients,18,21,22 and thus our results suggest-
ing a preference for monotherapy may seem contradictory. 
Previous studies did not assess combination therapy within 
the framework of other relevant (second-line) DMARD 
attributes though. We want to emphasize that our results are 
not intended to change any existing second-line treatment 
algorithms with currently available bDMARDs that mainly 
include combination with MTX. Nevertheless, patients’ 
preference for monotherapy should be considered for future 
treatment options, which may not need to be combined with 
MTX in order to achieve and maintain maximal efficacy.
With regard to frequency of administration, Poulus et al44 
reported RA patients to prefer treatment options to be taken 
in lower frequencies, unlike the “U-shaped” relationship we 
found. However, the highest frequency of administration 
in Poulus et al44 was “two treatments every week”, which 
corresponds to our second-highest frequency level (“every 
1–2 weeks”). Without a daily frequency level in our design, 
which was necessary by also including oral second-line treat-
ments, preferences would probably have increased linearly 
with lower frequencies in our study as well. Therefore, our 
findings seem in line with those by Poulos et al.44
However, findings by Augustovski et al,43 who used 
frequencies of administration that resembled our levels 
more closely (eg, “every day” as highest frequency) clearly 
contradict our findings. However, methodological differences 
between their study and ours could explain these divergent 
findings: while we excluded unrealistic level combinations 
(such as twice-daily infusions), Augustovski et al included 
all theoretically possible combinations in their design. In fact, 
a highly implausible combination was even used as reference 
case (“an oral agent taken every 10 months”), which has been 
previously noted to interfere with reasonable trade-offs.30 
Moreover, Augustovski et al43 included some entirely dif-
ferent attributes than our study, ie, cost and efficacy. Cost 
was not used in our DCE, as this attribute would be difficult 
to judge by our sample (in the German health care system, 
patients do not need to pay their RA treatment out of pocket); 
similarly, efficacy was not considered in our design, as it does 
not differ between relevant second-line treatments.9
More recently, yet another DCE study on examining 
patient preference in RA patients was performed by Louder 
et al.45 They conducted a choice-based conjoint survey in 
biologic-naïve RA patients using a methodology akin to 
count analysis. Across the seven attributes assessed, route of 
administration and frequency of administration were among 
the three most relevant for patient preference. For route of 
administration, patients mostly preferred oral intake and least 
favored infusion, so results are thus in line with our findings. 
Combination with MTX, which turned out to be the second 
relevant attribute of RA medication in our study, was not 
assessed in their trial. With regard to frequency of administra-
tion, the authors found a linear increase in preferences with 
lower frequencies, ie, every 8 weeks was most preferred and 
twice daily was least preferred. Notably, as in Augustovski 
et al,43 Louder et al45 included costs and efficacy parameters in 
their design – which we excluded for the reasons mentioned 
earlier – and did not control for implausible level combina-
tions in their design (eg, “oral intake once every 8 weeks”). 
Such design differences may well account for the divergent 
findings relative to our study.
While patient preferences did not markedly change 
when adjusting for various patient characteristics, adjusted 
regression analysis still yielded significant influences by 
patient variables on choices in the DCE. This suggests 
subgroups with specific preference profiles, despite these 
groups obviously sharing some highly similar preferences. 
Future research will examine more thoroughly to what extent 
individual patient characteristics need to be considered when 
analyzing preference data.
Conclusion
In summary the results suggest an oral DMARD that does not 
have to be combined with MTX and is administered either 
less or more often than on a weekly basis to be a highly 
favorable second-line treatment option for patients diagnosed 
with RA. DMARDs meeting these preferences may increase 
compliance and adherence in RA, and thus improve health 
outcomes and quality of life in affected individuals.
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